MedinCell S.A (MDCLF PINK) stock market data APIs
$7.0376
0(0%)
as of March 17, 2025
MedinCell S.A Financial Data Overview
MedinCell S.A., a pharmaceutical company, develops long acting injectables in various therapeutic areas in France. It develops solutions based on BEPO, a long-acting injectable technology; and offers UZEDY (mdc-IRM) for the treatment of schizophrenia in adults. The company's products in development include mdc-CWM, a sustained-release formulation of celecoxib in Phase III trials for use in the treatment of reduction of postoperative pain and inflammation; and mdc-TJK, a subcutaneous injection that is in Phase III clinical trials for use in the treatment of schizophrenia. Its product candidates in preclinical trials include mdc-WWM for contraception; and mdc-STM for malaria. MedinCell S.A. was incorporated in 2003 and is headquartered in Jacou, France.
Prev. Close
7.0376
Open
7.0376
High
7.0376
Low
7.0376
52 wk Range
6.9757-6.976
Market Cap
231 M
Shares Outstanding
33 060 K
Revenue
13 200 K
EPS
-0.2722
Beta
1.214
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get MedinCell S.A data using free add-ons & libraries
Get MedinCell S.A Fundamental Data
MedinCell S.A Fundamental data includes:
- Net Revenue: 13 200 K
- EBITDA: -18 810 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2021-09-30
- EPS/Forecast: 0
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
MedinCell S.A News
New
MedinCell’s Partner Teva Announces Successful Launch of UZEDY™
MONTPELLIER, France, August 02, 2023--(BUSINESS WIRE)--MedinCell (Paris:MEDCL): Access here the complete press release During today’s Q2 earnings call, Richard Francis, President and CEO of Teva, ...
MedinCell has Received the Last Tranche of €10m from the European Investment Bank (EIB) Loan
MONTPELLIER, France, July 31, 2023--(BUSINESS WIRE)--Regulatory News: MedinCell (Paris:MEDCL): The drawdown of this last tranche of a 40 million euros total loan signed with the EIB in November 2022...
MedinCell Announces the Availability of Its 2022-23 Universal Registration Document Including the Annual Financial Report
MONTPELLIER, France, July 31, 2023--(BUSINESS WIRE)--Regulatory News: MedinCell (Paris:MEDCL): The 2022-23 Universal Registration Document (URD) filed with the French market authority (Autorités de...
Half-Year Liquidity Contract Statement for MEDINCELL
PARIS, July 07, 2023--(BUSINESS WIRE)--Regulatory News: Under the liquidity contract entered into between MEDINCELL (Paris:MEDCL) and Kepler Cheuvreux, the following resources appeared on the liquidi...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
